Medplus Health Services Limited has informed stock exchanges about regulatory action taken against its subsidiary, involving the suspension of drug licenses for multiple store locations in Maharashtra.

Subsidiary Faces License Suspension Orders

Optival Health Solutions Private Limited, a subsidiary of Medplus Health Services, has received three suspension orders for drug licenses affecting stores in Maharashtra. The orders were received on December 13, 2025, from the Assistant Commissioner Licensing Authority, Food Drug Administration, Maharashtra.

The suspensions target stores located in Amravati and Nagpur districts, with each suspension lasting five days. The regulatory action has been taken under Rule 65 of the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945.

Financial Impact Assessment

The company has quantified the potential revenue impact from these license suspensions across the affected locations:

The total potential revenue loss across the affected locations is estimated at ₹10.17 lakhs.

Regulatory Compliance and Disclosure

The disclosure has been made pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, read with SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024. These regulations require listed entities to disclose material events affecting their operations or subsidiaries.

The company has stated that detailed information regarding this matter will be available on its official website at www.medplusindia.com , as well as on the websites of BSE Limited and National Stock Exchange of India Limited. This ensures transparency and accessibility of information for all stakeholders and regulatory compliance requirements.

MedPlus Health Services Limited has disclosed a regulatory development affecting one of its subsidiaries through a filing with stock exchanges on December 11, 2025. The company informed BSE Limited and National Stock Exchange of India Limited about a drug license suspension order received by its subsidiary Optival Health Solutions Private Limited.

Regulatory Action Details

The suspension order was issued by the Assistant and Director of Drug Control Administration, Bangalore Circle-5, Karnataka, targeting a specific store location. The affected store is situated at Ganganagar Bus Stop in Karnataka.

Legal Framework and Compliance

The suspension order was issued under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. This regulatory framework governs the licensing and operation of pharmaceutical retail establishments across India.

Financial Impact Assessment

The company has quantified the potential financial impact of this regulatory action. MedPlus Health Services estimates a potential revenue loss of ₹2.40 lacs resulting from the five-day suspension period.

Disclosure and Transparency

The disclosure was made pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, read with SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024. The company has ensured that this information will be available on its website at www.medplusindia.com , as well as on the websites of both stock exchanges.

The filing was signed by Manoj Kumar Srivastava, Company Secretary and Compliance Officer, demonstrating the company's commitment to regulatory compliance and transparent communication with stakeholders regarding material developments affecting its operations.